OTO-313

https://investors.otonomy.com/news-releases/news-release-details/otonomy-provides-update-otividexr-and-oto-313-programs

https://www.globenewswire.com/news-release/2020/11/30/2136417/0/en/Otonomy-Provides-Update-on-OTIVIDEX-and-OTO-313-Programs.html

Otonomy expects to start Phase 2 trial of OTO-313 in tinnitus in first quarter of 2021

https://www.globenewswire.com/news-release/2020/07/06/2058156/0/en/Otonomy-Reports-Positive-Top-Line-Results-from-Phase-1-2-Clinical-Trial-of-OTO-313-in-Patients-with-Tinnitus.html

Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

https://www.globenewswire.com/news-release/2020/06/15/2048357/0/en/Otonomy-Provides-Update-on-Clinical-Trials-and-Development-Programs.html

Otonomy Provides Update on Clinical Trials and Development Programs

June 15, 2020 16:05 ET | Source: Otonomy, Inc.

• Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021
• Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020
• Results from Phase 1/2 trial of OTO-413 in hearing loss expected in fourth quarter of 2020

SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and the timeline to results for the company’s three ongoing clinical trials, including the Phase 3 trial of OTIVIDEX in Ménière’s disease. The company will host a conference call and webcast today at 4:30 p.m. ET to review these updates.

https://clinicaltrials.gov/ct2/show/NCT03918109?type=Intr&cond=Tinnitus&phase=012345&lupd_s=04%2F03%2F2019&lupd_d=14

https://www.globenewswire.com/news-release/2019/04/11/1802608/0/en/Otonomy-Initiates-Phase-1-2-Clinical-Trial-of-OTO-313-in-Tinnitus.html